![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JA Widness, P Veng-Pedersen, RL Schmidt, LS Lowe, JA Kisthard and C Peters
College of Medicine, Department of Pediatrics, University of Iowa, Iowa City, USA.
Knowledge regarding the in vivo metabolic fate of the glycoprotein erythropoietin (EPO) is incomplete. To determine whether EPO pharmacokinetics are perturbed by ablation of the kidneys or liver or by anesthesia, EPO pharmacokinetic parameters were determined in adult sheep. Animals were studied in a paired manner, with and without deep barbiturate anesthesia and before and immediately after nephrectomy or hepatectomy accompanied by deep barbiturate anesthesia. Hepatectomy was accomplished with the liver left in situ, by occlusion of the arterial hepatic blood supply and diversion of portal venous flow to the jugular vein. After i.v. administration of tracer amounts of 125I-labeled recombinant human EPO, multiple blood samples were taken over 6 to 7 hr and analyzed for EPO immunoprecipitable radioactivity. EPO pharmacokinetic parameters were derived using a noncompartmental system analysis applied to the data on EPO immunoprecipitable radioactivity. No significant differences were detected for plasma clearance, distribution volume, mean residence time and alpha and beta half-lives examined under each of the three paired study conditions. Contrary to speculation by others, results of the present study make it highly unlikely that removal of the terminal sialic acid moieties of EPO contributes significantly to the metabolism of EPO. Because removal of the liver and kidney had no effect on EPO elimination, the metabolic degradation of EPO occurs in a tissue compartment that is yet to be defined. We speculate that the bone marrow is the most likely tissue with primary responsibility for the metabolism of EPO.
This article has been cited by other articles:
|
|
 |
|
  S. E. Juul, R. J. McPherson, L. A. Bauer, K. J. Ledbetter, C. A. Gleason, and D. E. Mayock A Phase I/II Trial of High-Dose Erythropoietin in Extremely Low Birth Weight Infants: Pharmacokinetics and Safety Pediatrics, August 1, 2008; 122(2): 383 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Artunc and T. Risler Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2900 - 2908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Woo and W. J. Jusko Interspecies Comparisons of Pharmacokinetics and Pharmacodynamics of Recombinant Human Erythropoietin Drug Metab. Dispos., September 1, 2007; 35(9): 1672 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Veng-Pedersen, S. Chapel, N. H. Al-Huniti, R. L. Schmidt, E. M. Sedars, R. J. Hohl, and J. A. Widness A Differential Pharmacokinetic Analysis of the Erythropoietin Receptor Population in Newborn and Adult Sheep J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 532 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ramakrishnan, W. K. Cheung, F. Farrell, L. Joffee, and W. J. Jusko Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin after Intravenous and Subcutaneous Dose Administration in Cynomolgus Monkeys J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 324 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chapel, P. Veng-Pedersen, R. J. Hohl, R. L. Schmidt, E. M. McGuire, and J. A. Widness Changes in Erythropoietin Pharmacokinetics following Busulfan-Induced Bone Marrow Ablation in Sheep: Evidence for Bone Marrow as a Major Erythropoietin Elimination Pathway J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 820 - 824. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
